glp 1 and gip glp 1 receptor agonists Schematic illustration of monoagonists, dual triple GLP-1 Receptor Agonists – Peripheral

GLP-1 receptor agonists and reduction of cardiometabolic risk: potential underlying mechanisms

Follow-up tirzepatide is $399/month

This broader understanding has helped drive interest in medically supervised treatment programs that take a more comprehensive approach

If GLP-1 medications reduce these risks, even partially, the implications for long-term lupus management are profound

These research efforts can prove the efficacy, safety, and real-world implications of GLP-1RAs as anti-inflammatory agents, ultimately informing treatment choices and improving patient care

Rhee CM, Ahmadi SF, Kovesdy CP, Kalantar-Zadeh K